A detailed history of Wellington Management Group LLP transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 10,727,450 shares of DNLI stock, worth $256 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
10,727,450
Previous 9,823,767 9.2%
Holding current value
$256 Million
Previous $228 Million 36.99%
% of portfolio
0.06%
Previous 0.04%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$20.96 - $31.05 $18.9 Million - $28.1 Million
903,683 Added 9.2%
10,727,450 $312 Million
Q2 2024

Aug 13, 2024

BUY
$14.96 - $23.22 $23.2 Million - $36.1 Million
1,553,818 Added 18.79%
9,823,767 $228 Million
Q1 2024

May 15, 2024

BUY
$15.83 - $23.35 $131 Million - $193 Million
8,269,949 New
8,269,949 $170 Million
Q4 2023

Feb 12, 2024

BUY
$16.2 - $23.18 $118 Million - $169 Million
7,274,717 New
7,274,717 $156 Million
Q3 2023

Nov 14, 2023

BUY
$20.63 - $30.17 $5.17 Million - $7.57 Million
250,784 Added 3.56%
7,288,960 $150 Million
Q2 2023

Aug 14, 2023

BUY
$23.37 - $32.96 $42.9 Million - $60.6 Million
1,837,716 Added 35.34%
7,038,176 $208 Million
Q1 2023

May 12, 2023

BUY
$21.91 - $32.67 $1.72 Million - $2.57 Million
78,730 Added 1.54%
5,200,460 $120 Million
Q4 2022

Feb 13, 2023

BUY
$26.28 - $33.92 $134 Million - $173 Million
5,100,036 Added 23508.97%
5,121,730 $142 Million
Q3 2022

Nov 14, 2022

BUY
$25.97 - $38.53 $563,393 - $835,869
21,694 New
21,694 $665,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.21B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.